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265 Prevalence and treatment of reduced BMD in a cystic ﬁbrosis
cohort undergoing lung transplantation
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Background: As life expectancy in cystic ﬁbrosis (CF) increases, long term
sequelae and their treatment assume greater importance. Osteoporosis is a prime
example.
Objectives: To examine the prevalence and treatment of reduced bone mineral
density (BMD) in CF patients referred for lung transplantation as a basis for
implementing improved clinical practice.
Methods: Single centre retrospective analysis of bone health and its management
in CF patients who underwent lung transplantation 01/2008−07/2012. We measured
BMD via dual-energy X-ray absorptiometry (DEXA) scan and examined multiple
risk factors for reduced BMD.
Results: 41 patients with CF underwent primary lung transplantation, comprising
63% females. Mean age at transplant was 27 years (95% CI 24−30), mean BMI
18.35 (95% CI 17.56–19.13). 5/41 patients (12%) had a documented history of
fracture. DEXA was undertaken in 39/41 (95%) of patients prior to transplantation,
with t-scores reported in 27/41 patients. The mean t-score at L2-L4 was −1.4 (95%
CI −1.0 to −1.8); and at the femoral neck −1.1 (95% CI −0.7 to −1.5). 13/27 (48%)
patients met WHO criteria for osteopenia and 6/27 (22%) for osteoporosis. There
was signiﬁcant variability in the measurement and treatment of risk factors.
Conclusions: Clinically signiﬁcant reduced BMD is frequent in CF patients referred
for consideration of lung transplantation. Treatment of reduced BMD and its risk
factors was variable, prompting implementation of a number of clinical practice
improvement measures including pre-emptive management prior to referral.
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Objectives: The increase in life expectancy of cystic ﬁbrosis (CF) patients has
raised new clinical problems like osteopenia and related fractures. The etiology of
osteopenia in CF is multi-factorial. Here, we aim to seach osteopenia and vitamin D
deﬁciency frequency in childen with CF.
Methods: Bone mineralization was assessed using a dual energy X-ray absorptiom-
etry (DXA) scan. Areal bone mineral density (BMD) values were determined as
g/cm2 and Z-score. Vitamin D level was assessed by plasma 25(OH)D3. 25 (OH)D3
level <10 ng/ml and 10−25 ng/ml was deﬁned as severe and mild to moderate
deﬁciency respectively.
Results: 24 children (50% female) were included. Mean age was 9.1±4.5 years.
20 (83%) patients were receiving vitamin D at 400–800 IU doses/day. The mean
BMD and Z-score were 0.87 and −0.81±1.1 respectively. Eleven patients (46%)
had decreased BMD values (Z-score <−1). The mean vitamin D level was
24.6±9.8 ng/ml and it was low in 58% (severe in 5%, mild to moderate in 53%)
of patients. BMD Z-score values were lower in patients with bacterial colonisation
with pseudomonas (p = 0.019) and 25(OH)D3 levels were lower in patients with
pancreas insufﬁciency (p = 0.03). No correlation was detected between vitamin D
levels and BMD Z-scores.
Conclusion: We conclude that osteopenia is a common problem in children with
CF and the infection and inﬂammation are the major etiologic factors, other than
the vitamin D levels in CF related osteopenia. However, the vitamin D deﬁciency
is very common in CF, even they are supplemented with vitamin D. Optimization
of vitamin D supplementation doses is required.
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Osteoporosis is frequent problem for adult patients with cystic ﬁbrosis (CF). But
more attention should be given to the effects of the disease on bone turnover and
bone mineral status especially in young patients.
Aim: To determine bone mineral status and markers of bone turnover in CF patients.
Methods: The study recruited 70 CF patients (range 5−32 y), 30 female, divided in
3 groups: prepubertal, pubertal and adults. Osteocalcin, bcrosslaps, PTH, 25OHD,
calcium, phosphorus and alkaline phosphatase in serum were investigate.
Results: Prepubertal group included 37 patients (range 5–11.99 y). Mean
value for osteocalcin was 81.06±21.1 ng/ml, for bcrosslaps 1.33±0.3 ng/ml,
25OHD was 25.56±12.1 ng/ml and PTH was 31.7±12.3 pg/ml. Calcium was
2.4±1.2mmol/l and alkaline phosphatase 240±12.3 IU. Pubertal group included
17 CF patients (range 12−18 y). Mean value for osteocalcin in this group was
77.03±11.2 ng/ml, for bcrosslaps 1.42±0.5 ng/ml, for 25OHD 22.07±10 ng/ml
and for PTH 40.6±11.3 pg/ml. Calcium was 2.3±1.3mmol/l and alkaline phos-
phatase 230±13.7 IU. The group with adult CF patients (range 19−32 y) has
osteocalcin 27.66±12.1 ng/ml, bcrosslaps0.58±0.3 ng/ml, 25OHD 20.4±13 ng/ml
and PTH 65.93±9.6 pg/ml. Calcium was 2.4±1.1mmol/l and alkaline phosphatase
240±11.6 IU. There was no difference in bone mineral status or for levels of vit.D
in all three groups. Levels of markers for bone turnover in serum were elevated in
prepubertal and pubertal children with CF.
Conclusion: There is a possibility of a very early onset of defective bone mineral-
ization in CF independent of severe inﬂammation and nutritional status.
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In Cystic Fibrosis (CF) renal function impairment is of major concern.
Objectives: To ascertain the prevalence of impaired renal function (GFR
<90ml/min) and associated risk factors in patients (pts) followed in our specialized
CF centre.
Methods: Renal function, demographics, genotype, FEV1, pancreatic status, BMI,
diabetes (CFRD), airways bacterial colonization, inhaled and iv aminoglycoside
use were registered. Patients were grouped according to their GFR: group A
(<90ml/min) and group B (90ml/min).
Results: 33 patients were studied, group A (13; 45%) and group B (20; 55%).
Proteinuria: 65.2±47.7 vs 28.8±28.3mg/d. Serum creatinine: 0.7±0.2 vs
0.8±0.2mg/dl. Cistatin C 0.61±0.06 vs 0.62±0.86mg/L. Age: 30±6.7 vs
24±5.4 yrs. Time since diagnosis: 15±12.8 vs 16±6.4 yrs. DelF508 mutation
identiﬁed 11 vs 17 pts. FEV1 pred was 47.6±19.5 vs 56.4±27.0%. Pseudomonas
aeruginosa chronic airways colonization: 10 vs 13 pts. Pancreatic insufﬁciency:
9 vs 13. BMI was 20.7±3.0 vs 19.6±3.2 kg/m2. Cumulative iv aminoglycoside
therapy: 26±39 vs 76±148 days. Inhaled aminoglycosides 8 vs 14 pts.
Conclusion: Patients with GFR impairment were older (p = 0.02, r2 = −0.41),
had more time elapsed since diagnosis and worst disease severity. Creatinine
clearance was negatively correlated (p = 0.002; r2 = −0.0.55) with proteinuria. GFR
impairment seems to be irrespective of genotype, airways colonization, CFRD, BMI,
antibiotic use, serical biomarkers.
Serial measurements of GFR and proteinuria are mandatory because GFR impair-
ment may ensue although serum creatinine remains normal.
